Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 06:05pm CEST

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
04/21 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – CFO Sold 503 shares of Stock
04/21 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – COO Sold 4,405 shares of Sto..
04/20 CHUGAI PHARMACEUTICAL : Reports Summarize Immunoglobulins Study Results from Chu..
04/20ROCHE HOLDING LTD. : quaterly sales release
04/20 REMINDER : Invitation to Roche’s First Quarter Sales 2017 Conference Call
04/19 ROCHE : FDA Grants Genentech's Tecentriq (Atezolizumab) Accelerated Approval as ..
04/19 ROCHE : Genentech Announces Positive Interim Results for Emicizumab in Phase III..
04/19 ROCHE : Genentech`s Tecentriq receives FDA-accelerated approval for advanced bla..
04/19 ROCHE : FDA grants Roche's TECENTRIQ® (atezolizumab) accelerated approval as ini..
04/19 ROCHE : FDA approves Roche's Lucentis (ranibizumab injection) for diabetic retin..
More news
Sector news : Pharmaceuticals - NEC
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/21 EMA hands down a number of recommendations
04/21 Medicare Drug Price Debate Puts Regeneron At Risk
04/21 Merck Leads Rivals In Novel Drug Approvals
04/20 Protalix BioTherapeutics Is Positioned Well For The Future
04/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 19, 2017
Advertisement
Financials ( CHF)
Sales 2017 53 106 M
EBIT 2017 18 532 M
Net income 2017 11 477 M
Debt 2017 8 747 M
Yield 2017 3,41%
P/E ratio 2017 18,54
P/E ratio 2018 16,93
EV / Sales 2017 4,25x
EV / Sales 2018 3,92x
Capitalization 216 757 M
More Financials
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 285  CHF
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.8.21%217 624
JOHNSON & JOHNSON5.69%330 078
PFIZER INC.3.57%200 330
NOVARTIS AG-1.08%192 857
MERCK & CO., INC.5.13%169 673
SANOFI7.10%114 121
More Results